Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | STAT6 | P42226 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346131 | 0.82 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL5667561 | 0.80 | LMNA (0.52) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4362204 | 0.77 | LMNA (0.47) | LMNAMAPTSTAT6KDM4EMEN1 | |
| SCHEMBL27997842 | 0.76 | TSHR (0.37) | LMNACA12CA1CA2CA3 | |
| SCHEMBL224075 | 0.75 | LMNA (0.46) | LMNAMAPTSTAT6KDM4EMEN1 | |
| SCHEMBL225114 | 0.75 | LMNA (0.46) | LMNAMAPTSTAT6KDM4EMEN1 | |
| SCHEMBL12764295 | 0.71 | — | — | |
| SCHEMBL1881639 | 0.71 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1881643 | 0.71 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1881641 | 0.71 | LMNA (0.48) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471533-B2 | Compound usable as cationic lipid | KYOWA KIRIN CO., LTD. (JP) | 2022-10-18 | — | — | US | disclosed |
| EP-3521270-B1 | CATIONIC LIPID COMPOUND | KYOWA KIRIN CO LTD (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-20210275672-A1 | COMPOUND USABLE AS CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2021-09-09 | — | — | US | disclosed |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | KYOWA KIRIN CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| EP-3162794-B1 | ALKYL SUBSTITUTED AZETIDINES AS CATIONIC LIPID | KYOWA KIRIN CO LTD (JP) | 2020-09-16 | — | — | EP | disclosed |
| EP-3662913-A1 | NUCLEIC-ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Kirin Co., Ltd. (JP) | 2020-06-10 | — | — | EP | disclosed |
| EP-3521270-A1 | CATIONIC LIPID COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20190008975-A1 | COMPOUND AS CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3395797-A1 | COMPOUNDS AS CATIONIC LIPIDS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-20170224619-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-3162794-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-05-03 | — | — | EP | disclosed |
| US-20170101639-A1 | RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF CKAP5 GENE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-04-13 | — | — | US | disclosed |
| EP-3153172-A1 | CKAP5-GENE-SILENCING RNAI PHARMACEUTICAL COMPOSITION | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11471533-B2 | Compound usable as cationic lipid | NPC1L1, PLIN1, PLIN5 | LMNA 278/4885CA12 4257/4885CA1 4258/4885 |
| US-20170224619-A1 | CATIONIC LIPID | NPC1L1, NPC1, SGMS1 | LMNA 256/4885CA12 3520/4885CA1 3498/4885 |
| US-20170101639-A1 | RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF CKAP5 GENE | ALKBH5, CKAP4, CTDSP1 | LMNA 548/4885CA12 3536/4885CA1 3133/4885 |
| US-20210275672-A1 | COMPOUND USABLE AS CATIONIC LIPID | NPC1L1, PLIN1, PLIN5 | LMNA 278/4885CA12 4257/4885CA1 4258/4885 |
| US-20190008975-A1 | COMPOUND AS CATIONIC LIPID | NPC1L1, LIPA, CETP | LMNA 2501/4885CA12 2378/4885CA1 3959/4885 |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | LIPA, LIPC, PNLIP | LMNA 570/4885CA12 2577/4885CA1 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.